Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

City of Hope Medical Center · NCT07224750

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
1000
US sites recruiting
1
Study start
June 21, 2024
Record last updated
July 7, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies. Current diagnostic approaches-including endoscopy, computed tomography (CT), and magnetic resonance imaging (MRI)-are either invasive, resource-intensive, or insufficiently sensitive for detecting early-stage disease, and are therefore not suitable for population-wide screening or for simultaneously identifying multiple GI tumor types. As a result, many patients are diagnosed at advanced stages, when therapeutic options are limited and prognosis is poor.

Circulating microRNAs (miRNAs) offer a promising alternative, as they are stable in peripheral blood and reflect tumor-related molecular alterations. In this study, the investigators aim to develop and validate a robust, noninvasive miRNA-based signature capable of distinguishing GI cancers from non-malignant controls. By integrating multi-cohort datasets and applying machine learning-based feature selection and predictive modeling, the investigators will construct a screening panel optimized for reproducibility, scalability, and early-stage detection. This noninvasive miRNA signature has the potential to support accessible, cost-effective, and clinically practical population-level screening for GI cancers, ultimately facilitating earlier diagnosis and improving outcomes for participants.

Conditions: Hepatocellular Carcinoma (HCC); Cholangiocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); Esophageal Squamous Cell Carcinoma (ESCC); Gastric Cancer (GC); Colorectal Cancer Screening

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Adults aged 18 years or older at the time of blood sample collection.
  • Patients with a confirmed diagnosis of one of the following gastrointestinal cancers: Hepatocellular carcinoma (HCC), Cholangiocarcinoma (CCA), Pancreatic ductal adenocarcinoma (PDAC), Esophageal squamous cell carcinoma (ESCC), Gastric cancer (GC), Colorectal cancer (CRC), Non-cancer control participants, including healthy volunteers or patients with benign gastrointestinal conditions.
  • Availability of retrospective blood samples collected according to institutional protocols.
  • Willingness to allow use of de-identified clinical and demographic data for research purposes.

Exclusion Criteria

  • other active malignancies; insufficient sample quality/volume; recent chemotherapy/radiotherapy/surgery; any condition preventing reliable participation.

Recruiting US locations

  • City of Hope Nat Medical Ctr

    Duarte, CA 91010

    Site contact: Ajay Goel, PhD · 6263598111 · ajgoel@coh.org

Study contacts (from the official record)

  • Junyong Weng, PhD · 06263151444 · juweng@coh.org
A Noninvasive and Screening miRNA Signature for Gastrointestinal… (NCT07224750) | Bored Studies